CASI Pharmaceuticals’ Partner Juventas Announces New Drug Application For CNCT19 Accepted By China National Medical Products Administration
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that China National Medical